Compare GNT & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNT | PEPG |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 113.3M |
| IPO Year | N/A | 2022 |
| Metric | GNT | PEPG |
|---|---|---|
| Price | $8.86 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.17 |
| AVG Volume (30 Days) | 65.6K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.87 | $1.01 |
| 52 Week High | $9.30 | $7.80 |
| Indicator | GNT | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 23.13 |
| Support Level | $7.76 | $1.57 |
| Resistance Level | $9.30 | $5.37 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 63.27 | 26.68 |
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.